Skip to content

Methods for assessing adverse cardiovascular events in elderly patients with comorbidities based on non-perturbation monitoring of vital signs: a multicenter clinical trial

Methods for assessing adverse cardiovascular events in elderly patients with comorbidities based on non-perturbation monitoring of vital signs: a multicenter clinical trial

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079346
Enrollment
Unknown
Registered
2024-01-01
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric comorbidities

Interventions

Non-disturbance monitoring group:Wearable armbands
Routine monitoring group:Return to the hospital on time for follow-up

Sponsors

General Hospital of Southern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Age = 65 years old and = 85 years old; (2) From 2023.06.01 to 2024.12.31, patients were admitted to the General Hospital of the Southern Theater and cooperative hospitals; (3) Patients with coronary heart disease combined with more than one of the following chronic diseases (including diabetes, renal insufficiency, stroke, hyperlipidemia, hyperuricemia); (4) According to the "2021 ESC Diagnosis and Management of Acute and Chronic Heart Failure", the previous = of heart failure was clearly diagnosed once; (5) NYHA cardiac function grade II.~III; (6) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Suffering from severe cardiovascular and cerebrovascular diseases: uncontrolled acute coronary syndrome; acute heart failure; cardiogenic shock; moderate-severe aortic stenosis, descending aortic aneurysm; acute aortic dissection; acute myocarditis, pericarditis, or endocarditis; obstructive hypertrophic cardiomyopathy; severe pulmonary hypertension; acute lower extremity deep vein and interscalene vein thrombosis; hypertensive emergencies; (2) Symptomatic or hemodynamically unstable arrhythmias, such as frequent short-bursting ventricular tachycardia, sustained ventricular tachycardia, etc.; Severe bradyarrhythmias, such as atrioventricular block of grade and above (except in pacemaker-implanted patients); (3) Acute pulmonary embolism and pulmonary infarction; acute respiratory failure; uncontrolled asthma; Resting peripheral oxygen saturation <85%; (4) Some clinical conditions that have not been corrected (such as severe anemia, electrolyte imbalance, hyperthyroidism, etc.); (5) acute uncontrolled infection; (6) Life expectancy is less than 3 months or is participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Heart failure worsens;

Secondary

MeasureTime frame
BNP change from baseline;6 minutes walk test;heart failure quality of life score;NYHA classification;all-cause mortality;death from cardiovascular causes;myocardial infarction;ischemic stroke;severe arrhythmia;readmission rate for cardiovascular events;Patient-reported outcomes;

Countries

China

Contacts

Public Contactxulin

General Hospital of Southern Theater Command

xxgnk_xlin@126.com+86 138 8990 8230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026